Literature DB >> 11884874

A long-term follow-up study of severe variant of central serous chorioretinopathy.

Sanae Otsuka1, Norio Ohba, Kumiko Nakao.   

Abstract

PURPOSE: To facilitate understanding of the long-term course and visual outcome of a severe variant of central serous chorioretinopathy.
DESIGN: Consecutive observational case series. PATIENTS AND METHODS: The authors reviewed 25 patients with multifocal posterior pigment epitheliopathy and bullous retinal detachment, who had a mean follow-up time of 10.6 years (range, 6-22 years), with reference to the demographic feature, fundus changes, recurrence, and final anatomic and visual outcome. Two patients underwent optical coherence tomography.
RESULTS: The patients were 21 men and 4 women, with a mean age at disease onset of 43.1 years (range, 30-63 years). Twenty-one patients were otherwise healthy, and four developed ocular disease during systemic corticosteroid therapy for metabolic or autoimmune diseases including systemic lupus erythematosus. The disease was bilateral in 21 patients (84%). Nine patients (36%) presented initially with classic central serous chorioretinopathy, followed by its severe variant 7 months to 9 years later. Active disease was characterized by multifocal exudative lesions in the posterior pole and bullous retinal detachment with shifting subretinal fluid in the inferior periphery. Optical coherence tomography of exudative lesions disclosed cloudy and fibrinous subretinal fluid. The exudative lesions were self-limited or responded to photocoagulation. During the follow-up period, 13 patients (52%) showed 1 to 5 recurrent disease, but the disease eventually became quiescent with multifocal atrophic scars in the posterior pole with or without atrophic tracts in the inferior periphery. Final best-corrected visual acuity was 2020 or better in 24 of 46 affected eyes (52%) of 25 patients and 2040 or better in 37 eyes (80.4%).
CONCLUSIONS: A severe variant of central serous chorioretinopathy characterized by multifocal posterior exudations and bullous inferior retinal detachment with shifting subretinal fluid may affect otherwise healthy, middle-aged males or individuals receiving systemic corticosteroid therapy for metabolic or autoimmune diseases. Exudative chorioretinal lesions are self-limited or respond to photocoagulation. Recurrence is common, but the disease eventually becomes quiescent with favorable visual acuity unless the macula is damaged.

Entities:  

Mesh:

Year:  2002        PMID: 11884874     DOI: 10.1097/00006982-200202000-00005

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  29 in total

1.  Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy.

Authors:  J A Montero; J M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

2.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

3.  Surgical management of bilateral exudative retinal detachment associated with central serous chorioretinopathy.

Authors:  Ji Eun Kang; Hyun Jin Kim; Hee Don Boo; Ha Kyoung Kim; Jeong Hee Lee
Journal:  Korean J Ophthalmol       Date:  2006-06

4.  [Spectral domain OCT in central serous chorioretinopathy: description of retinal changes].

Authors:  V Valet; C P Lohmann; M Maier
Journal:  Ophthalmologe       Date:  2012-09       Impact factor: 1.059

5.  [Selective retina therapy in central serous chorioretinopathy with detachment of the pigmentary epithelium].

Authors:  C Klatt; H Elsner; E Pörksen; R Brinkmann; A Bunse; R Birngruber; J Roider
Journal:  Ophthalmologe       Date:  2006-10       Impact factor: 1.059

6.  Severe bilateral central serous chorioretinopathy in a black patient: 16 years follow-up.

Authors:  John M Katsimpris; Constantin J Pournaras; Carlos W Sehgelmeble; Ioannis K Petropoulos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-05-12       Impact factor: 3.117

7.  Severe visual loss secondary to central serous chorioretinopathy following prolonged immune suppression with oral prednisolone.

Authors:  A Harikrishnan; K Anderson; S Patra
Journal:  JRSM Short Rep       Date:  2010-09-15

8.  Clinical efficiency of Helicobacter pylori eradication in the treatment of patients with acute central serous chorioretinopathy.

Authors:  Olesya Zavoloka; Pavlo Bezditko; Irina Lahorzhevska; Darya Zubkova; Yevgeniya Ilyina
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-03-16       Impact factor: 3.117

9.  [Intravitreal bevacizumab for chronic central serous chorioretinopathy].

Authors:  M F Niegel; N F Schrage; S Christmann; R F Degenring
Journal:  Ophthalmologe       Date:  2008-10       Impact factor: 1.059

10.  [Intraocular injections of bevacizumab in rare indications--two cases].

Authors:  T Wecke; C Knop; W Schreiber; W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.